BioSpace News Archive

FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close.

AEON Biopharma, Inc. announced the closing of its previously announced business combination with Priveterra Acquisition Corp., a special purpose acquisition company.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.

PaxMedica, Inc. today announced positive top line data for the Company’s PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).

ZyVersa Therapeutics, Inc. announced today the pricing of a “reasonable best efforts” public offering of 12,727,273 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 12,727,273 shares of common stock.

ARTBIO, Inc. (ARTBIO) and SpectronRx, a leading radiopharmaceutical developer and manufacturer, today announced a global strategic partnership agreement to support manufacturing of components of ARTBIO’s AlphaDirect™ isotope isolation technology.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development.

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., a global leader in generic and innovative medicines and Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that they have agreed to expand their existing strategic partnership agreement.

Opthea Limited announced that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the 2023 Opthalmology Innovation Summit being held in Seattle, WA on July 27th, 2023.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24th.